44.21 USD
+0.16 (+0.36%)
At close: Feb 10, 2026
42.622 USD
-1.59 (-3.59%)
After Hours: 2/10/2026, 8:00:02 PM
Taking everything into account, RPRX scores 6 out of 10 in our fundamental rating. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- RPRX had positive earnings in the past year.
- In the past year RPRX had a positive cash flow from operations.
- Each year in the past 5 years RPRX has been profitable.
- In the past 5 years RPRX always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.95%, RPRX belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
- RPRX's Return On Equity of 11.93% is amongst the best of the industry. RPRX outperforms 85.86% of its industry peers.
- The Return On Invested Capital of RPRX (6.43%) is better than 84.29% of its industry peers.
- RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.66%.
- The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- Looking at the Profit Margin, with a value of 32.55%, RPRX belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
- In the last couple of years the Profit Margin of RPRX has declined.
- RPRX has a better Operating Margin (65.22%) than 100.00% of its industry peers.
- In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
- Compared to 1 year ago, RPRX has less shares outstanding
- RPRX has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for RPRX is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 1.81 indicates that RPRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- RPRX's Altman-Z score of 1.81 is in line compared to the rest of the industry. RPRX outperforms 58.64% of its industry peers.
- The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
- RPRX has a Debt to FCF ratio of 9.47. This is in the better half of the industry: RPRX outperforms 79.58% of its industry peers.
- RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of RPRX (1.34) is worse than 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.81 |
ROIC/WACC0.74
WACC8.72%
2.3 Liquidity
- RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 54.97% of the companies in the same industry.
- A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 57.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
- RPRX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.23% yearly.
- Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
- RPRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.52% yearly.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
- RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.65% yearly.
EPS Next Y13.78%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
EPS Next 5Y10.53%
Revenue Next Year17.9%
Revenue Next 2Y9.71%
Revenue Next 3Y8.83%
Revenue Next 5Y10.65%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.76, which indicates a very decent valuation of RPRX.
- RPRX's Price/Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 90.58% of the companies in the same industry.
- RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.03.
- The Price/Forward Earnings ratio is 8.52, which indicates a very decent valuation of RPRX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 92.15% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of RPRX to the average of the S&P500 Index (27.97), we can say RPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.76 | ||
| Fwd PE | 8.52 |
4.2 Price Multiples
- 82.72% of the companies in the same industry are more expensive than RPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.01 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of RPRX may justify a higher PE ratio.
- A more expensive valuation may be justified as RPRX's earnings are expected to grow with 12.99% in the coming years.
PEG (NY)0.78
PEG (5Y)N/A
EPS Next 2Y12.48%
EPS Next 3Y12.99%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 2.13%, RPRX has a reasonable but not impressive dividend return.
- RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.93. RPRX pays more dividend than 92.67% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.80, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.13% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
44.21
+0.16 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-11 2026-02-11/bmo
Inst Owners81.5%
Inst Owner Change-1.3%
Ins Owners1.56%
Ins Owner Change-1.45%
Market Cap25.52B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target48.57 (9.86%)
Short Float %7.09%
Short Ratio6.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.13% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20 2026-02-20 (0.235)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)4.81%
PT rev (3m)9.5%
EPS NQ rev (1m)2.76%
EPS NQ rev (3m)1.5%
EPS NY rev (1m)-3.01%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)2.79%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.76 | ||
| Fwd PE | 8.52 | ||
| P/S | 10.86 | ||
| P/FCF | 27.01 | ||
| P/OCF | 10.61 | ||
| P/B | 3.98 | ||
| P/tB | 4.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY9.3%
EPS(NY)5.19
Fwd EY11.73%
FCF(TTM)1.64
FCFY3.7%
OCF(TTM)4.17
OCFY9.42%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.78
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.81 |
F-Score5
WACC8.72%
ROIC/WACC0.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y13.78%
EPS Next 2Y12.48%
EPS Next 3Y12.99%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year17.9%
Revenue Next 2Y9.71%
Revenue Next 3Y8.83%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.76 and the Price/Book (PB) ratio is 3.98.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.